WEC
VYGR icon

Winslow Evans & Crocker’s Voyager Therapeutics VYGR Stock Holding History

Winslow Evans & Crocker’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-286
Closed -$4K – 1167
2020
Q2 		$4K Hold
286
– – ﹤0.01% 945
2020
Q1 		$4K Hold
286
– – ﹤0.01% 949
2019
Q4 		$4K Hold
286
– – ﹤0.01% 1035
2019
Q3 		$6K Buy
+286
New +$6K ﹤0.01% 945

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Winslow Evans & Crocker's VYGR Position: Q3 2020 in Review

Winslow Evans & Crocker sold out of Voyager Therapeutics (VYGR) in Q3 2020, closing a stake of 286 shares — an estimated $4K sold.

Winslow Evans & Crocker first reported a position in VYGR in Q3 2019 and held it in 4 quarters. The position peaked at $6K in Q3 2019. 110 funds tracked by Wall St. Rank hold VYGR as of Q3 2020.

  • Winslow Evans & Crocker reported no remaining Voyager Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Winslow Evans & Crocker sold 286 Voyager Therapeutics shares in Q3 2020, an estimated $4K.
  • Winslow Evans & Crocker first reported a position in Voyager Therapeutics in Q3 2019 and held it in 4 quarters.
  • Winslow Evans & Crocker's Voyager Therapeutics position peaked at $6K in Q3 2019.
  • 110 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2020.

Based on Winslow Evans & Crocker's 13F filing for Q3 2020, filed 21 Oct 2020.